ライフサイエンスコーパス: sepsis syndrome

1 entified as a major source for this systemic sepsis syndrome.

2 on the outcome of mortality in patients with sepsis syndrome.

3 o play a pivotal role in the pathogenesis of sepsis syndrome.

4 regulating amplification of inflammation in sepsis syndrome.

5 psis syndrome and 50 in the patients without sepsis syndrome.

6 ic approach for prevention of I/R-associated sepsis syndrome.

7 thogenesis of Gram-negative bacteria-induced sepsis syndrome.

8 human IL-1Ra showed an absence of benefit in sepsis syndrome.

9 and subtypes of bacteremia in patients with sepsis syndrome.

10 ory cytokines may promote development of the sepsis syndrome.

11 nts following operative trauma or those with sepsis syndrome.

12 sopressors and inotropes in the treatment of sepsis syndrome.

13 a levels were also elevated in patients with sepsis syndrome.

14 daily for 3 days after presentation with the sepsis syndrome.

15 ant to the clinical outcome in patients with sepsis syndromes.

16 use in patients with acute inflammation and sepsis syndromes.

17 possibilities for therapeutic management of sepsis syndromes.

18 Sepsis syndrome, a systemic response to infection, can b

19 cterized by high mortality rates due to the "sepsis syndrome," a widespread and uncontrolled inflamma

20 he sterile inflammatory response to a lethal sepsis syndrome after lower torso I/R injury.

21 of 40 children with clinically overt severe sepsis syndrome and 30 children immediately postcardiopu

22 the OI at 24 hrs was 31 in the patients with sepsis syndrome and 50 in the patients without sepsis sy

23 om bacteria can result in the development of sepsis syndrome and acute lung injury.

24 tissue factor (TF) is frequently observed in sepsis syndrome and is documented in certain viral hemor

25 All patients developed features of sepsis syndrome and required intensive care treatment.

26 l hemorrhagic fever differ from those in the sepsis syndrome and should be studied and interpreted se

27 In bacteremia and sepsis syndrome and their consequent complications (incl

28 of systemic inflammatory response syndrome, Sepsis Syndrome, and days on antibiotics were three time

29 Disseminated tuberculosis, sepsis syndrome, and rifampicin resistance were associat

30 -10 circulates in the blood of patients with sepsis syndromes, and increased concentrations of IL-10

31 Sepsis and sepsis syndrome are leading causes of mortality througho

32 cure cardiac tolerance in the setting of the sepsis syndrome are poorly understood.

33 tical Care Medicine definitions of sepsis or sepsis syndrome as the basis of trial entry.

34 The unadjusted attack rate for sepsis syndrome between individual centers differed by a

35 hylactic administration of MPL mitigates the sepsis syndrome by reducing chemokine production and the

36 The clinically overt severe sepsis syndrome children had confirmed or highly suspect

37 Patients with sepsis syndrome commonly have low serum selenium levels.

38 rface polysaccharides) in attempts to modify sepsis syndromes, could be developed.

39 In an effort to improve upon the traditional sepsis syndrome definitions, the predisposition, infecti

40 monary bypass versus clinically overt severe sepsis syndrome descriptors included the following: age,

41 ian-diagnosed sepsis, septic shock, SIRS, or sepsis syndrome documented in the medical record (all co

42 and treatment of hospitalized patients with sepsis syndrome, especially as new and expensive therape

43 unexpected dose-limiting toxicities: grade 4 sepsis syndrome, grade 4 hypotension with grade 3 rash a

44 pulmonary bypass and clinically overt severe sepsis syndrome groups in children.

45 factor activation in the pathophysiology of sepsis syndrome has not been established.

46 Advances in our understanding of the sepsis syndrome have enabled researchers to identify new

47 eaths versus 60.7% of survivors, p = 0.001), sepsis syndrome (high lactate in 50.8% of deaths versus

48 Septic shock was present at onset of sepsis syndrome in 25% of patients.

49 w studies have described the epidemiology of sepsis syndrome in a hospitalwide population.

50 responses that can eventually cause a fatal sepsis syndrome in humans.

51 duces endotoxin tolerance and attenuates the sepsis syndrome in mice after CLP, would alter tissue-sp

52 tensify the potentially fatal effects of the sepsis syndrome in patients with trauma, infection, or h

53 This emphasizes the complexity of sepsis syndromes in relation with comorbid conditions an

54 Although the prevailing theory for the sepsis syndrome is a condition of uncontrolled inflammat

55 Sepsis syndrome is a leading cause of acute respiratory

56 Sepsis syndrome is a leading cause of mortality in hospi

57 Sepsis syndrome is characterized by a dysregulated infla

58 Sepsis syndrome is common in academic hospitals, althoug

59 Sepsis syndrome is frequently complicated by the develop

60 h concentrations of systemic TNF-alpha, this sepsis syndrome is short-lived and recovery is rapid and

61 standing of the hospitalwide epidemiology of sepsis syndrome is vital for rational planning and treat

62 During sepsis syndromes, lymphocyte apoptosis can be triggered

63 Acute inflammatory illnesses, including the sepsis syndrome, often include a component of coagulatio

64 ies included grade 4 stomatitis/pharyngitis, sepsis syndrome (one patient each), and grade 3 fatigue

65 trations were evaluated in 118 patients with sepsis syndrome or after elective operative trauma.

66 luble IL-1RII are increased in patients with sepsis syndrome or following thoraco-abdominal aneurysm

67 Survivors of sepsis syndrome or septic shock are characterized by an

68 ccording to predetermined criteria as having sepsis syndrome or septic shock were drawn retrospective

69 Part II: Eight patients admitted with sepsis syndrome over a 2-month period.

70 of 40 (87.5%) of the clinically overt severe sepsis syndrome patients and 29 of 30 (96.7%) of the pos

71 pulmonary bypass and clinically overt severe sepsis syndrome patients by receiver operating character

72 in optimizing the outcome of critically ill sepsis syndrome patients.

73 iguric mechanically ventilated patients with sepsis syndrome received LDD (3 micrograms/kg/min) or pl

74 The sepsis syndrome represents an improper immune response t

75 Induction of peritoneal sepsis syndrome resulted in a time-dependent increase in

76 As the sepsis syndrome results from the release of pro-inflamma

77 These observations suggest that abdominal sepsis syndrome results in significant impairment in AM

78 ealth Evaluation II, ICU residence on day 4, sepsis syndrome severity, antibiotic administration time

79 dmissions), cardiovascular disorders (nine), sepsis syndrome (six), neurologic disorders (four), moni

80 This may explain the sepsis syndrome that is seen with HSV (and other virus i

81 In the patients with sepsis syndrome, the model predicted a 90% probability o

82 therapies become available for patients with sepsis syndromes, the ability to predict mortality risk

83 e incidence (mean+/-95% confidence limit) of sepsis syndrome was 2.0+/-0.16 cases per 100 admissions,

84 Sepsis syndrome was defined as the presence of either a

85 stratified random sample of 1342 episodes of sepsis syndrome, was done in eight academic tertiary car

86 , phenylephrine, dopamine, and dobutamine in sepsis syndrome were considered if goal-directed therapy

87 patients were monitored and 1342 episodes of sepsis syndrome were documented.

88 of thoraco-abdominal aortic aneurysms and in sepsis syndrome, whereas concentrations were unaffected

89 e that evaluation of vasopressors earlier in sepsis syndrome will yield more promising results.

90 atients who met the established criteria for sepsis syndrome with multiple organ dysfunction syndrome